Publicaciones en las que colabora con Marta Suárez de Figueroa Díez (18)

2024

  1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

    Ophthalmology, Vol. 131, Núm. 6, pp. 708-723

  2. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

  3. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

2023

  1. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

    Japanese Journal of Ophthalmology, Vol. 67, Núm. 3, pp. 264-279

2022

  1. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

    Clinical and Experimental Ophthalmology, Vol. 50, Núm. 3, pp. 312-324

2021

  1. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

    Acta ophthalmologica, Vol. 99, Núm. 8, pp. 861-870

2019

  1. Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice

    Journal of Ophthalmology, Vol. 2019

2018

  1. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants

    Ophthalmologica, Vol. 240, Núm. 2, pp. 61-72

  2. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

2017

  1. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

    Ophthalmology Retina

2015

  1. A review of current management of vitreomacular traction and macular hole

    Journal of Ophthalmology, Vol. 2015

  2. Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration

    Current Opinion in Ophthalmology, Vol. 26, Núm. 3, pp. 200-205

  3. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  4. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia six years outcome

    Retina, Vol. 35, Núm. 12, pp. 2450-2456

  5. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

  2. Evaluation of macular retinal ganglion cell-inner plexiform layer thickness after vitrectomy with internal limiting membrane peeling for idiopathic macular holes

    BioMed Research International, Vol. 2014

2009

  1. Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa

    Archivos de la Sociedad Española de Oftalmologia, Vol. 84, Núm. 7, pp. 333-344